Advertisement
Dr. Mol will be responsible for all of Pepscans corporate functions andthe overall management and strategic direction of the company. He brings toPepscan more than 20 years of management experience in the internationalpharmaceutical industry.
Advertisement
Dr. Mol was previously at Schering Plough where he was Vice-Presidentresponsible for the global scientific development and commercial strategy ofa Phase III project in an alliance with a subsidiary of Merck-Serono. Dr. Molcommented, "I look forward to working with the highly professional andtalented team at Pepscan. It is exciting to contribute to the creation of newtherapeutic antibodies against currently intractable targets, using manmademimics of the biologically relevant part of the target".
"Dr. Mol has tremendous experience that will be very valuable to Pepscan.He has held multiple executive level roles, including general managementpositions in the USA and other countries, and executive director positions inglobal marketing and alliance management. With his track record as aresult-driven leader, I am confident that he will bring Pepscan to the nextlevel as a leading company in the field of protein mimicry, fully exploitingits proprietary CLIPS(TM) technology", said Wim Jongen, Chairman of the Board.
Joost van Bree Ph.D., who has been fully supportive of the change inbusiness focus towards CLIPS based technology has decided to step down as CEOand continue to work on the development of therapeutic vaccines. Mr. Jongensaid, "Joost has been instrumental in broadening the company portfolio andcreating the momentum for growth. His contribution has been enormous and inthis new phase of the company, he will continue to focus on the successfuldevelopment of the proprietary pipeline of the therapeutic vaccine portfolio".
Notes to the editor:
About Pepscan
Pepscan Holding NV is a privately owned company based in Lelystad, theNetherlands. The company focuses on immunotherapy. It has developed apipeline of therapeutic vaccine and antibody programs, of which the mostadvanced is in Phase II clinical testing. Pepscans proprietary CLIPS(TM)technology has been proven to yield functional antibodies reactive with arange of complex proteins, including GPCRs. For more information visithttp://www.pepscan.com.
About CLIPS(TM) technology
CLIPS(TM) (Chemical LInkage of Peptides onto Scaffolds) is a technologyto present one or more peptides in a structurally constrained configuration.These molecules behave as functional mimics of complex protein domains andhitherto have been used in antibody and vaccine programs to create superiorimmunogens in the induction and selection of antibodies against diseaserelevant protein targets. This is especially valuable in the case of proteinsthat are inaccessible as recombinant proteins (e.g. GPCRs, ion channels,patented proteins).
SOURCE Pepscan Holding N.V.
